It is often described as a “double-edged sword” because while IL-10 can limit chronic inflammation, potentially suppressing tumor initiation, in established cancers, IL-10 frequently contributes to immune evasion by the tumor [32]. This evidence concerns the gene IL10 and neoplasm.